Not applicableWithdrawnNCT04368897What this trial is testingIn-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease SeverityWho this might be right forSARS-CoV 2COVIDCOVID-19+3 more Applied Biology, Inc.
Testing effectiveness (Phase 2)Study completedNCT03124433What this trial is testingNeoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate CancerWho this might be right forCancer of the Prostate Singapore General Hospital 30
Not applicableLooking for participantsNCT07677267What this trial is testingReal-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide TetraxetanWho this might be right forProstatic Neoplasms, Castration-Resistant Novartis Pharmaceuticals 1,067
Not applicableWithdrawnNCT04530500What this trial is testingCOVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene ExpressionWho this might be right forCovid19Androgen Receptor Gene Overexpression University of California, Irvine
Testing effectiveness (Phase 2)Ended earlyNCT02457910What this trial is testingTaselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast CancerWho this might be right forEstrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more Vanderbilt-Ingram Cancer Center 30
Post-approval studies (Phase 4)Study completedNCT04776889What this trial is testingThe Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer PatientsWho this might be right forProstate Cancer Metastatic National Cancer Institute, Egypt 70
Large-scale testing (Phase 3)UnknownNCT03520478What this trial is testingSHR3680 in Treating Patients With Hormone Sensitive Prostate CancerWho this might be right forProstate CancerHormone-Dependent Prostate Cancer Jiangsu HengRui Medicine Co., Ltd. 654
Testing effectiveness (Phase 2)Looking for participantsNCT04946370What this trial is testingPhase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate CancerWho this might be right forProstate Cancer Weill Medical College of Cornell University 52
Testing effectiveness (Phase 2)Study completedNCT02130700What this trial is testingOral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast CancerWho this might be right forProstate Cancer Innocrin Pharmaceutical 17
Testing effectiveness (Phase 2)Study completedNCT02580448What this trial is testingCYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)Who this might be right forCancer of the BreastBreast CancerAdvanced Breast Cancer+4 more Innocrin Pharmaceutical 175
Testing effectiveness (Phase 2)Study completedNCT02463032What this trial is testingEfficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast CancerWho this might be right forER+ and AR+ Breast Cancer GTx 136
Testing effectiveness (Phase 2)Active Not RecruitingNCT05849298What this trial is testingA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCWho this might be right forProstatic Neoplasm Novartis Pharmaceuticals 49
Early research (Phase 1)Looking for participantsNCT07570979What this trial is testingInvestigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer (mCRPC) Novartis Pharmaceuticals 208
Early research (Phase 1)Study completedNCT01351688What this trial is testingAn Open Label Prostate Cancer Study in Japanese PatientsWho this might be right forProstate Cancer AstraZeneca 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT02749903What this trial is testingEnzalutamide for Patients With Androgen Receptor Positive Salivary CancersWho this might be right forSalivary Cancer Alliance for Clinical Trials in Oncology 46
Large-scale testing (Phase 3)Ended earlyNCT03055312What this trial is testingBicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast CancerWho this might be right forMetastatic Triple Negative Breast Cancer Sun Yat-sen University 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT04325828What this trial is testingApalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland CarcinomaWho this might be right forSalivary Gland Neoplasms Janssen Pharmaceutical K.K. 31
Testing effectiveness (Phase 2)Study completedNCT01875250What this trial is testingEnzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate CancerWho this might be right forProstate Cancer National Cancer Institute (NCI) 38
Large-scale testing (Phase 3)Ended earlyNCT04844749What this trial is testingEfficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting AgentWho this might be right forMetastatic Castration-resistant Prostate CancerAndrogen Resistant Prostatic Cancer Veru Inc. 105
Testing effectiveness (Phase 2)Study completedNCT01867333What this trial is testingEnzalutamide With or Without Vaccine Therapy for Advanced Prostate CancerWho this might be right forProstate Cancer National Cancer Institute (NCI) 57